Company Overview
About Beckley Psytech
Beckley Psytech is a UK-based clinical-stage biotechnology company developing psychedelic-derived medicines for neuropsychiatric disorders, with a primary focus on treatment-resistant depression (TRD). Its lead asset, BPL-003, is an intranasal formulation of 5-MeO-DMT (mebufotenin benzoate) designed to deliver a controlled, short-duration psychedelic experience under medical supervision. In July 2025, Beckley Psytech and its partner atai Life Sciences reported positive topline results from a Phase 2b trial of BPL-003, with a single 8mg dose achieving a 12.1-point reduction on standardized depression scales at day 29 — a clinically meaningful outcome.
Business Model & Competitive Advantage
Following these results, the U.S. FDA granted Breakthrough Therapy Designation to BPL-003 in October 2025, recognizing its potential to substantially improve over existing therapies for TRD. The company merged with atai Life Sciences to form AtaiBeckley Inc., which plans to initiate Phase 3 trials in Q2 2026 pending FDA alignment. Financial resources are projected to support operations into 2029. Beyond BPL-003, Beckley''s pipeline includes VLS-01 (a DMT buccal film for TRD, Phase 2 data expected H2 2026) and EMP-01 (an oral R-MDMA compound for social anxiety disorder).
Competitive Landscape 2025–2026
Beckley Psytech''s scientific heritage traces to the Beckley Foundation, a leading psychedelic research organization, giving the company deep roots in psychedelic pharmacology and clinical research. Its regulatory and clinical progress positions Beckley among the most advanced psychedelic medicine programs globally, alongside COMPASS Pathways. The company''s shorter-duration 5-MeO-DMT approach aims to improve clinical feasibility compared to longer psilocybin sessions.
Key Differentiators
Emerging Innovator
Beckley Psytech is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare Beckley Psytech with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Beckley Psytech? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Beckley Psytech Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Beckley Psytech vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →